We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > GSK’s Nucala

News List

AstraZeneca’s Fasenra puts more pressure on GSK’s Nucala with expanded NICE backing fiercepharma
January 08, 2019
Back in mid-2018, AstraZeneca’s Fasenra hit a speed bump as England’s drug cost watchdog recommended it only when GlaxoSmithKline’s rival asthma drug Nucala wasn’t appropriate. But now, the AZ drug is in the fast lane thanks to an expanded recommendation.
AstraZeneca’s Fasenra puts more pressure on GSK’s Nucala with expanded NICE backing fiercepharma
January 08, 2019
Back in mid-2018, AstraZeneca’s Fasenra hit a speed bump as England’s drug cost watchdog recommended it only when GlaxoSmithKline’s rival asthma drug Nucala wasn’t appropriate. But now, the AZ drug is in the fast lane thanks to an expanded recommendation.
Data show ‘enduring’ benefits of GSK’s Nucala pharmatimes
May 24, 2018
According to results of the COLUMBA trial, which GSK says is the longest study of an anti-IL5 biologic treatment in severe eosinophilic asthma to be reported